NCT01064141 - A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

November 30, 2012

Conditions

Dengue FeverDengue Hemorrhagic Fever

Interventions

BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus

0.5 mL, Subcutaneous

BIOLOGICAL

OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines

0.5 mL, Subcutaneous and 0.5 mL, Intravascular

BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines

0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous

BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)

0.5 mL Subcutaneous and 0.5 mL Subcutaneous

Trial Locations (1)

San Pablo